Magnetecs’ CGCI system creates an electromagnetic field that is largely contained in the electromagnetic array and focused in an area no larger than the patient’s chest.

The CGCI system is integrated with cardiac mapping and navigation technologies, including X-ray, intracardiac echocardiography (ICE), and other advanced electrophysiology lab technologies and equipment.

The company said clinical trials will be conducted at the hospital using CGCI for mapping and ablation procedures performed for patients who have arrhythmia.

The clinical trials will be used for regulatory submission of the robotic CGCI system with the Korea Food and Drug Administration (KFDA).

Magnetecs CMO, Brotman Hospital Clinical Electrophysiology Laboratory director and UCLA Medical School clinical professor Eli Gang said in addition to the research they are conducting at La Paz University Hospital and now planning at Yonsei University, they are developing protocols to conduct extensive clinical trials at Mount Sinai Medical Center in New York City and in several additional locations in the US, Canada and Europe.

"As the number of CGCI installation sites expands in accordance with our global regulatory strategy, we look forward to the commercialization of the robotic CGCI system so this technology can reach arrhythmia patients around the world," Gang said.